Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPerez, Ariel
dc.contributor.authorIacoboni García-Calvo, Gloria
dc.contributor.authorPenack, Olaf
dc.contributor.authorJentzsch, Liv
dc.contributor.authorCarpio Segura, Cecilia Carmen
dc.contributor.authorBarba Suñol, Pere
dc.contributor.authorRejeski, Kai
dc.contributor.authorBücklein, Veit
dc.date.accessioned2022-09-06T12:22:15Z
dc.date.available2022-09-06T12:22:15Z
dc.date.issued2022-05
dc.identifier.citationRejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer. 2022 May;10(5):e004475.
dc.identifier.issn2051-1426
dc.identifier.urihttps://hdl.handle.net/11351/8036
dc.descriptionNeoplàsies hematològiques; Receptors; Antigen quimèric
dc.description.sponsorshipThis work was supported by a Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) research grant provided within the Sonderforschungbereich SFB-TRR 388/1 2021-452881907, and DFG research grant 451580403 (to MS). The work was further supported by the Bavarian Elite Graduate Training Network (to MS), the Wilhelm-Sander Stiftung (to MS, project no. 20180871), the Else-Kröner-Fresenius Stiftung (to MS), and the Bavarian Center for Cancer Research (BZKF).
dc.language.isoeng
dc.publisherBMJ
dc.relation.ispartofseriesJournal for ImmunoTherapy of Cancer;10(5)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectCèl·lules B - Tumors - Tractament
dc.subjectImmunoteràpia
dc.subjectAntígens CD - Immunologia
dc.subject.meshLymphoma, Large B-Cell, Diffuse
dc.subject.mesh/therapy
dc.subject.meshImmunotherapy, Adoptive
dc.subject.meshAntigens, CD19
dc.titleThe CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1136/jitc-2021-004475
dc.subject.decslinfoma de células B grandes difuso
dc.subject.decs/terapia
dc.subject.decsinmunoterapia adoptiva
dc.subject.decsantígenos CD19
dc.relation.publishversionhttp://dx.doi.org/10.1136/jitc-2021-004475
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Rejeski K] Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK) Munich Site, and German Cancer Research Center, Heidelberg, Germany. [Perez A] Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA. Blood & Marrow Transplant Program, Miami Cancer Institute, Miami, Florida, USA. [Iacoboni G, Carpio C, Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma of Barcelona, Bellaterra, Spain. [Penack O] Department of Hematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. German Cancer Consortium (DKTK) Berlin Site, and German Cancer Research Center, Heidelberg, Germany. [Bücklein V] Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. [Jentzsch L] Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany
dc.identifier.pmid35580927
dc.identifier.wos000797594100008
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple